Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

Cancer

Volumn 115, Issue 23, 2009, Pages 5382-5393

  Quintás Cardama, Alfonso ^a   Kantarjian, Hagop ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BCR ABL1 mutations; Chronic myeloid leukemia; Homoharringtonine; Omacetaxine mepesuccinate; T315I

Indexed keywords

ALPHA INTERFERON; AMINO ACID; BCR ABL PROTEIN; CGX 653; CYTARABINE; HOMOHARRINGTONINE; IMATINIB; ISOLEUCINE; OMACETAXINE MEPESUCCINATE; PROTEIN TYROSINE KINASE INHIBITOR; THREONINE; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CEPHALOTAXUS; CHRONIC MYELOID LEUKEMIA; CONTINUOUS INFUSION; CYTOPENIA; DIARRHEA; DRUG DOSE ESCALATION; DRUG STRUCTURE; DRUG SYNTHESIS; FEVER; HUMAN; HYPOTENSION; INFECTION; INJECTION SITE REACTION; LOW DRUG DOSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; TACHYCARDIA; THROMBOCYTOPENIA;

ALGORITHMS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HARRINGTONINES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES;

EID: 72249090201     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24601     Document Type: Review

References (77)

1. Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien SM. Homoharringtonine: history, current research, and future direction. Cancer. 2001;92:1591-1605. (Pubitemid 32947845)
2. Powell RG, Weisleder D, Smith CR Jr, Rohwedder WK. Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahedron Lett. 1970;11:815-818.
3. Powell RG, Weisleder D, Smith CR Jr. Antitumor alkaloids for Cephalataxus harringtonia: structure and activity. J Pharm Sci. 1972;61:1227-1230.
4. [No authors listed] Harringtonine in acute leukemias. Clinical analysis of 31 cases. Chin Med J (Engl). 1977;3: 319-324.
5. [No authors listed] Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med J (Engl). 1976;2:263-272.
6. O'Brien S, Kantarjian H, Keating M, et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995; 86:3322-3326.
7. O'Brien S, Kantarjian H, Koller C, et al. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood. 1999; 93:4149-4153. (Pubitemid 29279257)
8. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566. (Pubitemid 26151518)
9. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079-1082. (Pubitemid 20102464)
10. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417. (Pubitemid 44903745)
11. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880. (Pubitemid 32743979)
12. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401. (Pubitemid 38938156)
13. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129-141. (Pubitemid 40248339)
14. Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science. 2001;293: 2163-2163
15. Fresno M, Jimenez A, Vazquez D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem. 1977;72:323-330. (Pubitemid 8022231)
16. Kuliczkowski K. Influence of harringtonine on human leukemia cell differentiation. Arch Immunol Ther Exp (Warsz). 1989;37:69-76. (Pubitemid 19274718)
17. Yinjun L, Jie J, Weilai X, Xiangming T. Homoharringtonine mediates myeloid cell apoptosis via up-regulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP). Am J Hematol. 2004;76:199-204. (Pubitemid 38828836)
18. Baaske DM, Heinstein P. Cytotoxicity and cell cycle specificity of homoharringtonine. Antimicrob Agents Chemother. 1977;12:298-300. (Pubitemid 8165802)
19. Visani G, Russo D, Ottaviani E, et al. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on "in vitro" growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors. Leukemia. 1997;11:624-628.
20. Tipping AJ, Mahon FX, Zafirides G, Lagarde V, Goldman JM, Melo JV. Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia. 2002;16:2349-2357. (Pubitemid 36054369)
21. Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001;97: 1999-2007.
22. Scappini B, Onida F, Kantarjian HM, et al. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer. 2002;94:2653-2662.
23. Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 2006;66:10959-10966. (Pubitemid 44876995)
24. Zhang ZY, Hou CH, Zhu YF. [A preliminary therapeutic analysis of 82 cases of chronic granulocytic leukemia treated with harringtonine]. Zhonghua Nei Ke Za Zhi. 1986;25: 156-157,190.
25. Institute of Materia Medica, Chinese Academy of Medical Services and Chinese People's Liberation Army, 187th Hospital. Studies on the antitumor constituents of Cephalotaxus hainanesis Li. Acta Chim Sinica. 1976;34: 283-287.
26. Institute of Materia Medica, Chinese Academy of Medical Sciences. The antitumor effects and pharmacologic actions of harringtonine. Chinese Med J. 1977;3:319-324.
27. Chinese People's Liberation Army, 187th Hospital. Homoharringtonine in the treatment of leukemias: clinical analysis of 72 cases. Chinese Med J. 1978;3:163-166.
28. Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep. 1984;68:1085-1091.
29. Coonley CJ, Warrell RP Jr, Young CW. Phase I trial of homoharringtonine administered as a 5-day continuous infusion. Cancer Treat Rep. 1983;67:693-696.
30. Stewart JA, Krakoff IH. Homoharringtonine: a phase I evaluation. Invest New Drugs. 1985;3:279-286.
31. Neidhart JA, Young DC, Derocher D, Metz EN. Phase I trial of homoharringtonine. Cancer Treat Rep. 1983;67:801-804.
32. Whitacre MY, Van Echo DA, Applefeld M, et al. Phase I study of homoharringtonine (NSC 141-633) [abstract]. Proc Am Soc Clin Oncol. 1985;26:359.
33. Neidhart JA, Young DC, Kraut E, Howinstein B, Metz EN. Phase I trial of homoharringtonine administered by prolonged continuous infusion. Cancer Res. 1986;46:967-969. (Pubitemid 16145464)
34. Feun LG, Savaraj N, Landy H, Levin H, Lampidis T. Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors. J Neurooncol. 1990;9:159-163. (Pubitemid 20319395)
35. Witte RS, Hsieh P, Elson P, Oken MM, Trump DL. A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer. Invest New Drugs. 1996;14:409-413. (Pubitemid 27075450)
36. Witte RS, Lipsitz S, Goodman TL, et al. A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer. Invest New Drugs. 1999;17:173-177.
37. Runge-Morris MA, Kies MS, Vokes E, et al. Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council Study. Invest New Drugs. 1989;7:269-273. (Pubitemid 19202374)
38. Warrell RP Jr, Coonley CJ, Gee TS. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. J Clin Oncol. 1985;3:617-621.
39. Stewart JA, Cassileth PA, Bennett JM, O'Connell MJ. Continuous infusion homoharringtonine (NSC 141633) in refractory acute nonlymphocytic leukemia. An ECOG pilot study Am J Clin Oncol. 1988;11:627-629.
40. Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer. 1989;63:813-817.
41. Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia. 1992;6:1185-1188.
42. Tan CT, Hancock C, Steinherz P, et al. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer. Cancer Res. 1987;47:2990-2995. (Pubitemid 17113449)
43. Arlin Z, Feldman E, Biguzzi S, et al. Phase I/II trial of homoharringtonine in acute leukemia [abstract]. Proc Am Soc Clin Oncol. 1987;6:160.
44. Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia. 1992;6:1189-1191.
45. O'Brien S, Giles F, Talpaz M, et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer. 2003;98:888-893. (Pubitemid 37022086)
46. Kantarjian HM, Talpaz M, Smith TL, et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2000;18:3513-3521. (Pubitemid 30783331)
47. Stone RM, Donohue KA, Stock W, et al. Cancer and Leukemia Group B. A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol. 2009;63:859-864.
48. Ernst T, Vance E, Alyea E III, et al. Homoharringtonine and low-dose ara-C is a highly effective combination for the treatment of CML in chronic phase [abstract]. Blood (ASH Annual Meeting Abstracts). 1997;90:571a.
49. O'Brien S, Talpaz M, Cortes J, et al. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 2002;94:2024-2032. (Pubitemid 34270056)
50. Robin J, Dhal R, Dujardin G, Girodier L, Mevellec L, Poutot S. The first semi-synthesis of enantiopure homoharringtonine via anhydrohomoharringtonine from a preformed chiral acyl moiety. Tetrahedron Lett. 1999;40:2931-2934. (Pubitemid 29156607)
51. Tang R, Faussat AM, Majdak P, et al. Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol Cancer Ther. 2006;5:723-731.
52. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A. 1993;90:3516-3520. (Pubitemid 23111397)
53. Kuroda J, Kimura S, Andreeff M, et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol. 2008;140:181-190. (Pubitemid 350265045)
54. Lou YJ, Qian WB, Jin J. Homoharringtonine induces apoptosis and growth arrest in human myeloma cells. Leuk Lymphoma. 2007;48:1400-1406. (Pubitemid 47079368)
55. Kuroda J, Kamitsuji Y, Kimura S, et al. Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and betacatenin. Int J Hematol. 2008;87:507-515.
56. Jin W, Wu J, Zhuang Z, et al. Gene expression profiling in apoptotic k562 cells treated by homoharringtonine. Acta Biochim Biophys Sin (Shanghai). 2007;39:982-991. (Pubitemid 350274288)
57. Michaels S, Brown D, Segal D. Analysis of transcription factor expression after homoharringtonine treatment [abstract]. In: Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; April 14-18, 2007; Los Angeles, Calif. Philadelphia, Pa: AACR; 2007;48. Abstract 4843.
58. Chen Y, Hu Y, Michaels S, et al. Inhibitory effects of homoharringtonine on leukemic stem cells and BCR-ABL induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110:Page. Abstract 2912.
59. Burton C, Ranger A, Nadal E, et al. Semi-synthetic homoharringtonine (Myelostat®) for chronic myeloid leukemia in accelerated phase after imatinib failure [abstract]. Blood (ASH Annual Meeting Abstracts). 2003;102:908a-909a.
60. Maloisel F, Rousselot P, Morariu R. Subcutaneous hemisynthetic homoharringtonine (HHT) in combination with imatinib mesylate (Gleevec) in patients (PTS) with STI-resistant chronic myelogenous leukemia (CML): preliminary results of a pilot study [abstract]. Blood (ASH Annual Meeting Abstracts). 2003;102:909a.
61. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007;109:248-255. (Pubitemid 46106239)
62. Marin D, Kaeda JS, Andreasson C, et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer. 2005;103: 1850-1855. (Pubitemid 40563257)
63. Quintas-Cardama A, Kantarjian HM, Wierda W, et al. A phase II study of intravenous (IV) homoharringtonine (HHT) and imatinib (IM) in patients (pts) with chronic myeloid leukemia (CML) [abstract]. Blood (ASH Annual Meeting Abstracts). 2006;108:Page. Abstract 2174.
64. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science. 2000;289:1938-1942. (Pubitemid 30704121)
65. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI- 571). Cancer Res. 2002;62:4236-4243. (Pubitemid 34827278)
66. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol. 2008;15:1109-1118.
67. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042. (Pubitemid 32267973)
68. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib- resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-2551. (Pubitemid 43882350)
69. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib- resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-2541. (Pubitemid 43882349)
70. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2- chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin- 1-yl)-2- methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004; 47:6658-6661. (Pubitemid 40053752)
71. de Lavallade H, Khorashad JS, Davis HP, et al. Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation. Blood. 2007; 110:2779-2780. (Pubitemid 47523217)
72. Legros L, Hayette S, Nicolini FE, et al. BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge? Leukemia. 2007;21:2204-2206.
73. Cortes J, Khoury HJ, Corm S, et al. Safety and efficacy of subcutaneous (SC) omacetaxine mepesuccinate in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients with the T315I mutation - results of an ongoing multicenter phase 2/3 study [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112:Page. Abstract 3239.
74. Quintas-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov. 2007;6:834-848. (Pubitemid 47500507)
75. Noronha G, Cao J, Chow CP, et al. Inhibitors of ABL and the ABL-T315I mutation. Curr Top Med Chem. 2008;8:905-921.
76. Quintas-Cardama A, Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res. 2008;14:4392-4399.
77. Brown D, Michaels S. Design and evaluation of oral delivery dosage forms of homoharringtonine [abstract]. In: Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; April 14-18, 2007; Los Angeles, Calif. Philadelphia, Pa: AACR; 2007:48:Page. Abstract 4730.